Dysregulated monocyte iron homeostasis and erythropoietin formation in patients with anemia of chronic disease
6 million CKD patients requiring treatment for anemia of chronic disease every year that could potentially benefit from a hepcidin inhibitor in the combined markets of the EU-5 (France, Germany, Italy, Spain and the United Kingdom), Japan and the United States.
Cytokine-induced synthesis of hepcidin plays a crucial role in macrophage iron retention, which underlies the anemia of chronic disease by limiting the availability of iron for erythroid progenitor cells.
The anemia of chronic disease
comprises various clinical conditions with prominent signs of chronic inflammation and increased plasma concentrations of inflammatory cytokines such as tumor necrosis factor-[alpha] (TNF-[alpha]), interleukin-6 (IL-6), IL-1[beta], and interferon-[gamma].
Progress in understanding the pathogenesis of the anemia of chronic disease
NOX-H94 targets hepcidin, the key regulator of iron metabolism and mediator of iron restriction in anemia of chronic disease
, and is currently in Phase I.
2005) FG-2216: Tumor Progression Studies and Correction of Anemia of Chronic Disease
in Xenograft Models (Abstract F-PO672).
The expression of transferrin receptors on erythroblasts in anemia of chronic disease
, myelodysplastic syndromes and iron deficiency.
Through this collaboration, FibroGen is also positioned to address the larger, multi-million patient market opportunities currently not penetrated and addressed by rHuEPO products, including: chronic kidney disease (CKD) patients who are not yet on dialysis (pre-dialysis) and who are under the care of primary care physicians, patients having cancer-related anemias, patients with anemia associated with congestive heart failure (CHF), age-related anemia patients, and patients with anemia of chronic disease
Sera from 78 patients with iron deficiency anemia (IDA), anemia of chronic disease
, and ID in the presence of a complicating inflammatory condition (COMBI) were assayed to evaluate the ability to detect ID in the presence of COMBI.
today announced that advances in the development of FG-2216 for the treatment of anemia and FG-4592, a pioneering therapy for the anemia of chronic disease
(ACD), were reported at the American Society of Nephrology (ASN) 38th Annual Meeting & Scientific Exposition, November 8-13, Philadelphia, Pennsylvania.
Because circulating transferrin receptor concentrations do not increase in anemia secondary to inflammatory disorders [30, 31], they are helpful for distinguishing anemia of chronic disease
from iron-deficiency anemia [30, 32].
In addition to the clinical study results of FG-2216 regarding induction of endogenous EPO and of reticulocytes, the Company presented preclinical data demonstrating the ability of FG-2216 and other erythropoiesis-stimulating FibroGen HIF-PH inhibitors to overcome inflammatory cytokine-mediated suppression of EPO secretion, to improve iron status and microcytosis and reverse anemia in a model of anemia of chronic disease
, and to correct anemia in preclinical models of end-stage renal disease and cisplatin-induced anemia.
Thirty-six patients, who presented with stainable iron in the bone marrow, were classified as having anemia of chronic disease
Differentiation of iron deficiency and the anemia of chronic disease